SynAct Pharma AB · GETTEX:8F8
SynAct Pharma AB financial statements
SynAct Pharma AB's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 617.0K | 778.0K | 1.06M | 88.0K | 338.5K | 303.6K | 252.0K | 190.4K | ||
| Gross profit | 0 | 0 | 0 | 0 | 0 | -338.5K | -303.6K | -252.0K | -190.4K | |
| Research and development | 85.6M | 49.3M | 105.1M | 70.1M | 60.5M | 22.8M | 15.2K | 21.8M | ||
| Selling, general and administrative | 31.5M | 40.5M | 33.9M | 35.6M | 16.2M | 8.81M | 24.2M | 28.1M | 17.9M | |
| Operating income | -116.5M | -90.0M | -224.5M | -105.7M | -76.7M | -31.3M | -24.8M | -28.4M | -18.2M | -17.0M |
| Depreciation and amortization | 628.0K | 614.0K | 75.3M | 1.02M | 88.0K | 381.1K | 338.5K | 303.6K | 252.0K | 190.4K |
| EBITDA | -115.9M | -89.4M | -149.2M | -104.7M | -76.6M | -30.9M | -24.5M | -28.1M | -17.9M | -16.8M |
| Interest expense | 3.87M | 2.96M | 830.0K | 1.42M | 110.0K | 39.0K | 2.39M | 146.7K | 155.4K | |
| Income before tax | -119.0M | -90.8M | -224.3M | -107.1M | -76.8M | -31.3M | -27.1M | -28.2M | -18.0M | -17.0M |
| Income tax | -8.16M | -8.42M | -8.47M | -7.86M | -7.50M | -4.75M | -3.15M | -4.80M | -2.64M | -1.54M |
| Net income | -110.8M | -82.4M | -215.8M | -99.2M | -69.3M | -26.6M | -24.0M | -23.4M | -15.4M | -15.5M |
| Earnings per share, basic | -2.17 | -2.08 | -6.64 | -3.60 | -2.68 | -1.23 | -1.62 | -1.70 | -1.24 | -1.30 |
| Earnings per share, diluted | -2.17 | -2.08 | -6.64 | -3.60 | -2.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 53.4M | 61.2M | 62.4M | 108.2M | 24.0M | 14.5M | 3.56M | 7.12M | 10.2M | 26.6M |
| Short-term investments | 93.0K | 180.0K | -208.0K | |||||||
| Receivables | 13.4M | 5.96M | 12.4M | 14.7M | 10.7M | 6.46M | 4.90M | 6.02M | 3.87M | 2.92M |
| Inventory | -12.4M | 246.0K | 321.0K | -22.2K | -6.02M | -3.87M | -2.92M | |||
| Current assets | 71.3M | 94.0M | 75.1M | 140.2M | 34.9M | 21.3M | 8.45M | 13.1M | 14.1M | 29.5M |
| Property, plant and equipment | 2.10M | 3.18M | ||||||||
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 220.5M | 270.5M | 228.0M | 142.6M | 38.4M | 21.6M | 23.8M | 14.0M | 15.2M | 30.6M |
| Accounts payable | 9.49M | 17.3M | 9.67M | 4.72M | 4.25M | 2.77M | 5.46M | 3.23M | 1.78M | 3.16M |
| Current liabilities | 21.5M | 28.5M | 24.9M | 15.0M | 15.4M | 5.72M | 10.3M | 3.72M | 2.31M | 3.49M |
| Total debt | 1.81M | 1.88M | 637.0K | 2.06M | 3.09M | |||||
| Total liabilities | 50.2M | 56.4M | 51.8M | 16.1M | 17.5M | 5.72M | 10.3M | 3.72M | 2.31M | 3.49M |
| Shareholders' equity | 170.3M | 214.2M | 176.2M | 126.5M | 20.9M | 15.9M | 13.5M | 10.3M | 12.9M | 27.1M |
| Shares outstanding | 51.1M | 39.5M | 32.5M | 27.6M | 26.0M | 21.7M | 14.8M | 13.8M | 12.4M | 11.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -97.3M | -89.2M | -100.2M | -117.6M | -65.0M | -33.2M | -16.1M | -24.2M | -17.2M | -14.7M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -33.2M | -499.0K | 0 | -264.5K | -903.0K |
| Free cash flow | -97.3M | -89.2M | -100.2M | -117.6M | -65.0M | -33.2M | -16.6M | -24.2M | -17.5M | -15.6M |
| Cash from investing | 0 | 0 | 370.0K | 27.0K | -6.00K | -93.0K | -499.0K | -93.0K | -264.5K | -996.1K |
| Cash from financing | 90.5M | 87.4M | 54.0M | 200.7M | 74.3M | 44.7M | 13.0M | 20.8M | 950.9K | 42.1M |
| Change in cash | -6.87M | -1.79M | -45.8M | 83.2M | 9.32M | 11.0M | -3.56M | -3.09M | -16.4M | 25.8M |